{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:09:58Z","timestamp":1791007798606,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11,1]]},"abstract":"<jats:title>Learning Objectives<\/jats:title>\n               <jats:p>After completing this course, the reader will be able to: Describe the clinical and radiologic manifestations of RPLS.Define agents or inciting risk factors that have been implicated in the development of RPLS.Describe the treatment and outcome of RPLS, emphasizing supportive care and urgent discontinuation of the offending agent.<\/jats:p>\n               <jats:p>Access and take the CME test online and receive 1 AMA PRA Category 1 Credit\u2122 at CME.TheOncologist.com<\/jats:p>","DOI":"10.1634\/theoncologist.12-11-1332","type":"journal-article","created":{"date-parts":[[2007,11,30]],"date-time":"2007-11-30T19:39:01Z","timestamp":1196451541000},"page":"1332-1335","source":"Crossref","is-referenced-by-count":56,"title":["Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature"],"prefix":"10.1093","volume":"12","author":[{"given":"Anita","family":"Rajasekhar","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, College of Medicine, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Thomas J.","family":"George","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, College of Medicine, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,11,1]]},"reference":[{"key":"2021122208425293900_R1","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021122208425293900_R2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.lungcan.2006.01.006","article-title":"Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial","volume":"52","author":"Brodowicz","year":"2006","journal-title":"Lung Cancer"},{"key":"2021122208425293900_R3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000076330","article-title":"Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer","volume":"66","author":"Delfino","year":"2004","journal-title":"Oncology"},{"issue":"14","key":"2021122208425293900_R4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/jco.2004.22.90140.510","article-title":"Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival","volume":"22","author":"Albain","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122208425293900_R5","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208425293900_R6","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122208425293900_R7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/ajhp\/54.2.162","article-title":"Gemcitabine: A cytadine analogue active against solid tumors","volume":"54","author":"Hui","year":"1997","journal-title":"Am J Health Syst Pharm"},{"key":"2021122208425293900_R8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.1991.9.4.679","article-title":"Cytarabine and neurologic toxicity","volume":"9","author":"Baker","year":"1991","journal-title":"J Clin Oncol"},{"issue":"suppl 11","key":"2021122208425293900_R9","first-page":"3","article-title":"Gemcitabine: Metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin Oncol"},{"key":"2021122208425293900_R10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ajh.20772","article-title":"Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia","volume":"82","author":"Saito","year":"2007","journal-title":"Am J Hematol"},{"key":"2021122208425293900_R11","volume-title":"Gemzar\u00ae (gemcitabine HCl for injection) [package insert]","author":"Eli Lilly and Company","year":"2006"},{"key":"2021122208425293900_R12","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1445-5994.1999.tb00795.x","article-title":"Gemcitabine and the blood brain barrier","volume":"29","author":"Davis","year":"1999","journal-title":"Aust N Z J Med"},{"key":"2021122208425293900_R13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0730-725X(01)00217-X","article-title":"Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings","volume":"19","author":"Russell","year":"2001","journal-title":"Magn Reson Imaging"},{"key":"2021122208425293900_R14","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/02841860410018494","article-title":"Severe neurotoxicity caused by gemcitabine treatment","volume":"43","author":"Larsen","year":"2004","journal-title":"Acta Oncol"},{"key":"2021122208425293900_R15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N Engl J Med"},{"key":"2021122208425293900_R16","first-page":"1199","article-title":"Posterior reversible encephalopathy syndrome: Utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions","volume":"21","author":"Casey","year":"2000","journal-title":"AJNR Am J Neuroradiol"},{"key":"2021122208425293900_R17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00234-005-1376-6","article-title":"Posterior reversible encephalopathy syndrome: A possible late interaction between cytotoxic agents and general anesthesia","volume":"47","author":"Rangi","year":"2005","journal-title":"Neuroradiology"},{"key":"2021122208425293900_R18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ajh.20147","article-title":"Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies","volume":"77","author":"Tam","year":"2004","journal-title":"Am J Hematol"},{"key":"2021122208425293900_R19","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archneur.63.10.1475","article-title":"Reversible posterior leukoencephalopathy syndrome after bevacizumab\/FOLFIRI regimen for metastatic colon cancer","volume":"63","author":"Allen","year":"2006","journal-title":"Arch Neurol"},{"key":"2021122208425293900_R20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMc052954","article-title":"Reversible posterior leukoencephalopathy syndrome and bevacizumab","volume":"354","author":"Glusker","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122208425293900_R21","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1200\/JCO.2006.08.4608","article-title":"Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43\u20139006","volume":"24:28","author":"Govindarajan","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208425293900_R22","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1200\/JCO.2007.10.9991","article-title":"Dexamethasone-induced posterior reversible encephalopathy syndrome","volume":"25","author":"Irvin","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122208425293900_R23","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/rheumatology\/keh305","article-title":"A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion","volume":"43","author":"Mavragani","year":"2004","journal-title":"Rheumatology (Oxford)"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.12-11-1332","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.12-11-1332","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/11\/1332\/41835698\/oncolo_12_11_1332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/11\/1332\/41835698\/oncolo_12_11_1332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T15:09:23Z","timestamp":1640185763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/12\/11\/1332\/6398768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,1]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2007,11,1]]},"published-print":{"date-parts":[[2007,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.12-11-1332","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,11,1]]},"published":{"date-parts":[[2007,11,1]]}}}